238 related articles for article (PubMed ID: 31640190)
1. A Machine Learning-Based Prediction Platform for P-Glycoprotein Modulators and Its Validation by Molecular Docking.
Kadioglu O; Efferth T
Cells; 2019 Oct; 8(10):. PubMed ID: 31640190
[TBL] [Abstract][Full Text] [Related]
2. Homology Modeling of the Human P-glycoprotein (ABCB1) and Insights into Ligand Binding through Molecular Docking Studies.
Mora Lagares L; Minovski N; Caballero Alfonso AY; Benfenati E; Wellens S; Culot M; Gosselet F; Novič M
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517082
[TBL] [Abstract][Full Text] [Related]
3. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
[TBL] [Abstract][Full Text] [Related]
4. Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein.
Bikadi Z; Hazai I; Malik D; Jemnitz K; Veres Z; Hari P; Ni Z; Loo TW; Clarke DM; Hazai E; Mao Q
PLoS One; 2011; 6(10):e25815. PubMed ID: 21991360
[TBL] [Abstract][Full Text] [Related]
5. Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors.
Poongavanam V; Haider N; Ecker GF
Bioorg Med Chem; 2012 Sep; 20(18):5388-95. PubMed ID: 22595422
[TBL] [Abstract][Full Text] [Related]
6. Development of Simplified in Vitro P-Glycoprotein Substrate Assay and in Silico Prediction Models To Evaluate Transport Potential of P-Glycoprotein.
Ohashi R; Watanabe R; Esaki T; Taniguchi T; Torimoto-Katori N; Watanabe T; Ogasawara Y; Takahashi T; Tsukimoto M; Mizuguchi K
Mol Pharm; 2019 May; 16(5):1851-1863. PubMed ID: 30933526
[TBL] [Abstract][Full Text] [Related]
7. Caffeic Acid Attenuates Multi-Drug Resistance in Cancer Cells by Inhibiting Efflux Function of Human P-glycoprotein.
Teng YN; Wang CCN; Liao WC; Lan YH; Hung CC
Molecules; 2020 Jan; 25(2):. PubMed ID: 31936160
[No Abstract] [Full Text] [Related]
8. Predicting binding to p-glycoprotein by flexible receptor docking.
Dolghih E; Bryant C; Renslo AR; Jacobson MP
PLoS Comput Biol; 2011 Jun; 7(6):e1002083. PubMed ID: 21731480
[TBL] [Abstract][Full Text] [Related]
9. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Lee TD; Lee OW; Brimacombe KR; Chen L; Guha R; Lusvarghi S; Tebase BG; Klumpp-Thomas C; Robey RW; Ambudkar SV; Shen M; Gottesman MM; Hall MD
Mol Pharmacol; 2019 Nov; 96(5):629-640. PubMed ID: 31515284
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
11. Overlapping ligand specificity of P-glycoprotein and serum alpha(1)-acid glycoprotein: evidences and potential implications.
Zsila F
Curr Drug Metab; 2007 Aug; 8(6):563-93. PubMed ID: 17691918
[TBL] [Abstract][Full Text] [Related]
12. Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells.
Dinić J; Podolski-Renić A; Jovanović M; Musso L; Tsakovska I; Pajeva I; Dallavalle S; Pešić M
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31527404
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy.
Breier A; Barancík M; Sulová Z; Uhrík B
Curr Cancer Drug Targets; 2005 Sep; 5(6):457-68. PubMed ID: 16178819
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of cucurbitacin E from Citrullus colocynthis against multidrug-resistant cancer cells.
Saeed MEM; Boulos JC; Elhaboub G; Rigano D; Saab A; Loizzo MR; Hassan LEA; Sugimoto Y; Piacente S; Tundis R; Yagi S; Khalid H; Efferth T
Phytomedicine; 2019 Sep; 62():152945. PubMed ID: 31132750
[TBL] [Abstract][Full Text] [Related]
15. In silico model for P-glycoprotein substrate prediction: insights from molecular dynamics and in vitro studies.
Prajapati R; Singh U; Patil A; Khomane KS; Bagul P; Bansal AK; Sangamwar AT
J Comput Aided Mol Des; 2013 Apr; 27(4):347-63. PubMed ID: 23612916
[TBL] [Abstract][Full Text] [Related]
16. Development of a syngeneic in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator, PGP-4008.
Lee BD; French KJ; Zhuang Y; Smith CD
Oncol Res; 2003; 14(1):49-60. PubMed ID: 14552591
[TBL] [Abstract][Full Text] [Related]
17. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
18. Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment.
Waghray D; Zhang Q
J Med Chem; 2018 Jun; 61(12):5108-5121. PubMed ID: 29251920
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
20. Computational models for identifying potential P-glycoprotein substrates and inhibitors.
Crivori P; Reinach B; Pezzetta D; Poggesi I
Mol Pharm; 2006; 3(1):33-44. PubMed ID: 16686367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
